274 related articles for article (PubMed ID: 23669331)
41. Managing emerging mutagenicity risks: Late stage mutagenic impurity control within the atovaquone second generation synthesis.
Urquhart MWJ; Bardsley B; Edwards AJ; Giddings A; Griva E; Harvey J; Hermitage S; King F; Leach S; Lesurf C; McKinlay C; Oxley P; Pham TN; Simpson A; Smith E; Stevenson N; Wade C; White A; Wooster N
Regul Toxicol Pharmacol; 2018 Nov; 99():22-32. PubMed ID: 30118726
[TBL] [Abstract][Full Text] [Related]
42. Mutagenicity assessment of two potential impurities in preparations of 5-amino-2,4,6 triiodoisophthalic acid, a key intermediate in the synthesis of the iodinated contrast agent iopamidol.
Rossi S; Bussi S; Bonafè R; Incardona C; Vurro E; Visigalli M; Buonsanti F; Fretta R
Mutat Res Genet Toxicol Environ Mutagen; 2024 Jan; 893():503720. PubMed ID: 38272634
[TBL] [Abstract][Full Text] [Related]
43. Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: is aromatic N-oxide a structural alert for predicting DNA-reactive mutagenicity?
Amberg A; Anger LT; Bercu J; Bower D; Cross KP; Custer L; Harvey JS; Hasselgren C; Honma M; Johnson C; Jolly R; Kenyon MO; Kruhlak NL; Leavitt P; Quigley DP; Miller S; Snodin D; Stavitskaya L; Teasdale A; Trejo-Martin A; White AT; Wichard J; Myatt GJ
Mutagenesis; 2019 Mar; 34(1):67-82. PubMed ID: 30189015
[TBL] [Abstract][Full Text] [Related]
44. Characterization of false positive, contaminant-driven mutagenicity in impurities associated with the sotorasib drug substance.
Coppi A; Davies R; Wegesser T; Ishida K; Karmel J; Han J; Aiello F; Xie Y; Corbett MT; Parsons AT; Monticello TM; Minocherhomji S
Regul Toxicol Pharmacol; 2022 Jun; 131():105162. PubMed ID: 35331777
[TBL] [Abstract][Full Text] [Related]
45. Simple and alpha,beta-unsaturated aldehydes: correct prediction of genotoxic activity through structure-activity relationship models.
Benigni R; Conti L; Crebelli R; Rodomonte A; Vari' MR
Environ Mol Mutagen; 2005 Dec; 46(4):268-80. PubMed ID: 15991240
[TBL] [Abstract][Full Text] [Related]
46. Integrated in silico and in vitro genotoxicity assessment of thirteen data-poor substances.
Tran YK; Buick JK; Keir JLA; Williams A; Swartz CD; Recio L; White PA; Lambert IB; Yauk CL
Regul Toxicol Pharmacol; 2019 Oct; 107():104427. PubMed ID: 31336127
[TBL] [Abstract][Full Text] [Related]
47. Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens.
Jacobson-Kram D; Contrera JF
Toxicol Sci; 2007 Mar; 96(1):16-20. PubMed ID: 17194803
[TBL] [Abstract][Full Text] [Related]
48. Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project.
Honma M; Kitazawa A; Cayley A; Williams RV; Barber C; Hanser T; Saiakhov R; Chakravarti S; Myatt GJ; Cross KP; Benfenati E; Raitano G; Mekenyan O; Petkov P; Bossa C; Benigni R; Battistelli CL; Giuliani A; Tcheremenskaia O; DeMeo C; Norinder U; Koga H; Jose C; Jeliazkova N; Kochev N; Paskaleva V; Yang C; Daga PR; Clark RD; Rathman J
Mutagenesis; 2019 Mar; 34(1):3-16. PubMed ID: 30357358
[TBL] [Abstract][Full Text] [Related]
49. Application of advanced in silico methods for predictive modeling and information integration.
Valerio LG
Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):395-8. PubMed ID: 22432718
[TBL] [Abstract][Full Text] [Related]
50. Distinguishing between expert and statistical systems for application under ICH M7.
Barber C; Hanser T; Judson P; Williams R
Regul Toxicol Pharmacol; 2017 Mar; 84():124-130. PubMed ID: 28057482
[No Abstract] [Full Text] [Related]
51. The importance of expert review to clarify ambiguous situations for (Q)SAR predictions under ICH M7.
Foster RS; Fowkes A; Cayley A; Thresher A; Werner AD; Barber CG; Kocks G; Tennant RE; Williams RV; Kane S; Stalford SA
Genes Environ; 2020; 42():27. PubMed ID: 32983286
[TBL] [Abstract][Full Text] [Related]
52. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
53. Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity.
Tcheremenskaia O; Benigni R
Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):987-1005. PubMed ID: 34078212
[No Abstract] [Full Text] [Related]
54. In Silico Approaches in Predictive Genetic Toxicology.
Sinha M; Dhawan A; Parthasarathi R
Methods Mol Biol; 2019; 2031():351-373. PubMed ID: 31473971
[TBL] [Abstract][Full Text] [Related]
55. An assessment of mutagenicity of chemical substances by (quantitative) structure-activity relationship.
Honma M
Genes Environ; 2020; 42():23. PubMed ID: 32626544
[TBL] [Abstract][Full Text] [Related]
56. Integrated approach to assess the domain of applicability of some commercial (Q)SAR models.
Kulkarni SA; Zhu J
SAR QSAR Environ Res; 2008; 19(1-2):39-54. PubMed ID: 18311633
[TBL] [Abstract][Full Text] [Related]
57. Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives.
Benfenati E; Benigni R; Demarini DM; Helma C; Kirkland D; Martin TM; Mazzatorta P; Ouédraogo-Arras G; Richard AM; Schilter B; Schoonen WG; Snyder RD; Yang C
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2009 Apr; 27(2):57-90. PubMed ID: 19412856
[TBL] [Abstract][Full Text] [Related]
58. International regulatory requirements for genotoxicity testing for pharmaceuticals used in human medicine, and their impurities and metabolites.
Galloway SM
Environ Mol Mutagen; 2017 Jun; 58(5):296-324. PubMed ID: 28299826
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of aromatic amines with different purities and different solvent vehicles in the Ames test.
Harding AP; Popelier PL; Harvey J; Giddings A; Foster G; Kranz M
Regul Toxicol Pharmacol; 2015 Mar; 71(2):244-50. PubMed ID: 25542092
[TBL] [Abstract][Full Text] [Related]
60. Genetic toxicology in silico protocol.
Hasselgren C; Ahlberg E; Akahori Y; Amberg A; Anger LT; Atienzar F; Auerbach S; Beilke L; Bellion P; Benigni R; Bercu J; Booth ED; Bower D; Brigo A; Cammerer Z; Cronin MTD; Crooks I; Cross KP; Custer L; Dobo K; Doktorova T; Faulkner D; Ford KA; Fortin MC; Frericks M; Gad-McDonald SE; Gellatly N; Gerets H; Gervais V; Glowienke S; Van Gompel J; Harvey JS; Hillegass J; Honma M; Hsieh JH; Hsu CW; Barton-Maclaren TS; Johnson C; Jolly R; Jones D; Kemper R; Kenyon MO; Kruhlak NL; Kulkarni SA; Kümmerer K; Leavitt P; Masten S; Miller S; Moudgal C; Muster W; Paulino A; Lo Piparo E; Powley M; Quigley DP; Reddy MV; Richarz AN; Schilter B; Snyder RD; Stavitskaya L; Stidl R; Szabo DT; Teasdale A; Tice RR; Trejo-Martin A; Vuorinen A; Wall BA; Watts P; White AT; Wichard J; Witt KL; Woolley A; Woolley D; Zwickl C; Myatt GJ
Regul Toxicol Pharmacol; 2019 Oct; 107():104403. PubMed ID: 31195068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
